Intellia Therapeutics (NTLA) Total Liabilities (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Total Liabilities data on file, last reported at $137.8 million in Q1 2026.

• Quarterly Total Liabilities fell 33.17% year-over-year to $137.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $137.8 million (down 33.17% YoY) and the FY2025 annual result came in at $170.7 million, down 46.49% from the prior year.
• Total Liabilities eased to $137.8 million in Q1 2026 per NTLA's latest filing, from $170.7 million in the prior quarter.
• Across five years, Total Liabilities topped out at $319.1 million in Q4 2024 and bottomed at $137.8 million in Q1 2026.
• The 5-year median for Total Liabilities is $220.5 million (2024), against an average of $222.0 million.
• The widest annual swing landed in 2022, when Total Liabilities soared 45.62%; it then plunged 46.49% in 2025.
• Tracing NTLA's Total Liabilities over 5 years: stood at $284.5 million in 2022, then declined by 11.85% to $250.8 million in 2023, then gained by 27.21% to $319.1 million in 2024, then sank by 46.49% to $170.7 million in 2025, then slipped by 19.27% to $137.8 million in 2026.
• Per Business Quant, the three latest NTLA Total Liabilities figures stand at $137.8 million (Q1 2026), $170.7 million (Q4 2025), and $176.9 million (Q3 2025).

Peer Comparison